Melanoma is the most lethal form of skin cancer. Therapeutic alternatives to metastatic melanoma are very limited. Activation of RAS pathway appears to be the central motor driving melanoma development and maintenance, where BRAFV600E and NRASQ61L are found in ~ 50% and 20% of human melanomas, respectively. Although, these mutually exclusive mutations affect the same pathway emerging preclinical a ...